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Abstract 
Aims 
The benefit of self-monitoring of blood glucose (SMBG) in the reduction of HbA1c in non-insulin-
treated participants remains unclear. HbA1c may be improved in this population with SMBG. We 
aimed to investigate this. 
Materials and methods 
Meta-analyses of randomized controlled trials (RCTs) were performed comparing SMBG versus 
usual care and structured versus unstructured SMBG; the effect of clinician therapy adjustment 
based on SMBG readings was examined. Medline, Embase and Cochrane Central were 
electronically searched to identify articles published from 1 January 2000 to 30 June 2020. Trials 
investigating changes in HbA1c were selected. Screening was performed independently by two 
investigators. Two investigators extracted HbA1c at baseline and follow-up for each trial. 
Results 
Nineteen RCTs, involving 4,965 participants were included. Overall, SMBG reduced HbA1c. 
Preplanned subgroup analysis showed that using SMBG readings to adjust therapy contributed 
significantly to the reduction. No significant improvement in HbA1c was shown in SMBG without 
therapy adjustment). The same difference was observed in structured SMBG compared to 
unstructured SMBG. 
Conclusions 
HbA1c is improved with therapy adjustment based on structured SMBG readings. Implications are 
for clinicians to prescribe structured SMBG with an aim for therapy adjustment based on the 
readings, and not prescribing unstructured SMBG. Participants with suboptimal glycemic control 
may benefit most. A SMBG regimen that improves clinical- and cost-effectiveness is presented. 
Future studies can investigate this regimen specifically. 
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More than 450 million people live with diabetes worldwide and this is projected to rise to 700 2 
million by 2045; over 90% of these live with type 2 diabetes (International Diabetes Federation 3 
(IDF), 2019). Glycemic control is the fundamental part of diabetes management (UKPDS Study 4 
Group, 1995), where glycosylated hemoglobin (HbA1c) is the main measure for its evaluation, 5 
strongly predicting diabetes complications (Stratton et al., 2000). The American Diabetes 6 
Association (ADA), Chinese Diabetes Society (CDS), and European Association for the Study of 7 
Diabetes (EASD) (Davies et al., 2018; Jia et al., 2019) recommend maintaining a HbA1c of ≤7% 8 
(53 mmol/mol) to significantly improve prognosis and reduce the risk of diabetes complications 9 
(Davies et al., 2018; Jia et al., 2019). 10 
Blood glucose is closely linked to glycemic control: blood glucose readings strongly indicate 11 
HbA1c (Nathan et al., 2008). However, the effectiveness of self-monitoring of blood glucose 12 
(SMBG) on glycemic control in non-insulin-treated participants remains unclear (Davies et al., 13 
2018). Investigating SMBG frequencies, Xu et al. (2019) report that up to 14 SMBG readings a 14 
week reduce HbA1c. Two early meta-analyses (Malanda et al., 2012; Zhu et al., 2016) supported 15 
this result, however, warned that reductions in HbA1c did not achieve clinical significance, calling 16 
for further evidence. A recent meta-analysis investigated SMBG though included participants on 17 
insulin (Machry et al., 2018). Another meta-analysis only included trials up to 2015 (Mannucci et 18 
al., 2018). 19 
The lack of clarity of SMBG benefit in non-insulin-treated participants may contribute to 20 
reluctance by clinicians (e.g., nurses) to prescribe SMBG in this population. This suggests a need 21 
for further evaluation of the effects of SMBG on HbA1c in non-insulin-treated participants with 22 
type 2 diabetes to prevent disease. 23 





Structured SMBG may afford better glycemic control. Structured SMBG has previously been 25 
regarded as testing blood glucose according to a defined regimen, with readings utilized to make 26 
appropriate therapy adjustments (participants or clinicians adjusting therapy based on SMBG 27 
readings e.g., oral hypoglycemic agents or lifestyle) (Parkin et al., 2012). However, definitions of 28 
structured SMBG have evolved and there is no current consensus (Davies et al., 2018; IDF, 2018; 29 
Parkin et al., 2012). For example, the ADA, EASD, and IDF do not offer a definition in their latest 30 
guidelines nor an optimal regimen, although the IDF provides examples for the latter: five-point 31 
or seven-point with paired (pre- and post-prandial) readings and at bedtime, or a “staggered” 32 
regimen (paired for alternate meals) (Davies et al., 2018; IDF, 2018). In this review, structured 33 
SMBG is considered as a SMBG regimen with times for SMBG readings clearly defined (e.g., 34 
three-point [such as pre-prandial for three main meals] twice weekly) which may or may not be 35 
“staggered”. Furthermore, therapy adjustment is considered as clinicians adjusting therapy based 36 
on SMBG readings. The ADA, EASD, and IDF recommend prescribing SMBG with therapy 37 
adjustment; however, this is based on expert consensus and not empirical evidence (Davies et al., 38 
2018; IDF, 2018); the IDF calls for further evidence (IDF, 2018). Accordingly, the current review 39 
addresses this call and implements an updated tool for assessing the risk of bias, not used in 40 
previous SMBG meta-analyses. This review and meta-analysis updates and extends the latest 41 
review (Mannucci et al., 2018), to explore if new trials and analysis, and investigating structured 42 
readings and therapy adjustment, have new implications for SMBG. Therefore, the aims of this 43 
review were to assess the effect of I) SMBG versus usual care and II) structured SMBG versus 44 
unstructured SMBG, on glycemic control in non-insulin-treated participants with type 2 diabetes, 45 
and extend with further analysis: III) SMBG readings used to adjust therapy versus usual care. 46 





MATERIALS AND METHODS 48 
This review is an update and extension to a recent review (Mannucci et al., 2018), which includes 49 
trials up to 2015. The search strategy presented in this paper was first used for studies up to 2015 50 
which resulted in the same trials being identified as in the previous review (Mannucci et al., 2018) 51 
along with seven more recent trials. This review is presented according to the statement for 52 
preferred reporting items for systematic review and meta-analysis (PRISMA) (Moher et al., 2015). 53 
The protocol is not published elsewhere; it is registered with the International Prospective Register 54 
of Systematic Reviews (Chircop et al., 2019) – CRD42019157463. 55 
 56 
Data Sources and Searches 57 
Multiple initial scoping searches were executed by using preliminary versions of the search 58 
strategy, which allowed for both scoping of the literature and refinement of the final search 59 
strategy. This allowed the identification of all relevant key-words and to assure that no other 60 
reviews existed on what is being investigated. An electronic search was carried out on the 61 
databases, namely Medline, Embase, and Cochrane Central; search results up to 18 October 2019 62 
were eligible. Search alerts for newly published articles matching the search were implemented 63 
for these databases until 30 June 2020. A search was performed on http://www.clnicaltrials.gov 64 
for any unpublished studies up to 18 October 2019. In addition, reference lists of retrieved studies 65 
were searched for other relevant studies. Recent journal issues related to the care of diabetes were 66 
searched up to 30 June 2020. An electronic search was performed to identify relevant studies that 67 
have cited previous reviews (Machry et al., 2018; Malanda et al., 2012; Mannucci et al., 2018; Xu 68 




et al., 2019; Zhu et al., 2016). The search strategy included the following terms: blood glucose 69 
self-monitoring, SMBG, blood glucose monitoring, BGM, glycemic control, HbA1c, A1c, 70 
glycosylated hemoglobin, type 2 diabetes mellitus, and T2DM. Search terms were combined with 71 
Boolean operators. Truncation and wild cards were used to produce an exhaustive search. The 72 
search was limited to studies published from the year 2000 onwards because of significant 73 
improvements in blood glucose meters (e.g., decreased waiting time and sample size) (Clarke & 74 
Foster, 2012). 75 
 76 
Study Selection 77 
The inclusion criteria included type 2 diabetes, non-insulin-treated participants, the investigation 78 
of HbA1c, and RCTs. For structured SMBG, the inclusion criteria included a SMBG regimen, 79 
which is clearly defined, with ≥10 readings every two months. Exclusion criteria included type 1 80 
diabetes, insulin-treated participants, the investigation of parameters other than HbA1c, continuous 81 
glucose monitoring, telemonitoring, telecare, observational, retrospective, and single-arm trials, 82 
and languages other than English, Italian, and Japanese. Usual care was considered as care that 83 
would have otherwise (if not enrolled in a trial) been received and that an intervention group would 84 
also be receiving; this may include no SMBG, or SMBG as necessary if considered essential by a 85 
clinician (e.g., hypoglycemic episodes). Screening first took place on the titles, then abstracts, and 86 
lastly full-text articles. Screening of the full-text articles and data extraction were performed 87 
independently by JC and DS. Disagreements (6.8%) were addressed through discussion; after 88 
clarifying the selection criteria, there was a 100% agreement eliminating the need to consult YK. 89 
 90 




Data Extraction and Quality Assessment 91 
The following data were extracted from each trial: i) authors and year of publication, ii) trial 92 
duration, iii) number of participants and age, iv) type of analysis, v) type of SMBG, vi) education 93 
or support provided, vii) health setting, viii) clinician who adjusted therapy, ix) baseline HbA1c, x) 94 
HbA1c at follow-up, and xi) funding. JC and DS independently extracted and compared data, and 95 
any disagreements were addressed through discussion. The quality of the trials was assessed 96 
independently by JC, DS and YK with Cochrane Risk of Bias 2 (RoB2) (Sterne et al., 2019). This 97 
tool permits a more accurate risk of bias assessment compared to RoB1: when blinding of 98 
participants is not possible (such as when a placebo is not possible), this considers whether 99 
allocation concealment (blinding of outcome assessors) would likely affect the outcome of an 100 
intended intervention (Sterne et al., 2019). Discrepancies (5.6%) and disagreements (33%) with 101 
the data extraction and quality assessment respectively were addressed through discussion. 102 
Consensus was reached without the need for YK to make a final decision. 103 
 104 
Data Synthesis and Analysis 105 
The outcome for all analyses was the difference in HbA1c between intervention and control groups. 106 
Data from intention-to-treat analysis were used; if these were unavailable, per-protocol data were 107 
used. All data were reported with ±1.96 standard deviation (SD) or 95% confidence intervals (CI). 108 
Mean changes in HbA1c were analyzed as continuous variables using mean difference changes 109 
between baseline and the last follow-up group available, and their CI as summary measures. The 110 
last follow-up groups available included at three, six, nine, 12, and 24 months. For each trial, the 111 
mean changes from baseline within the groups and their SD were extracted; if not available, the 112 




mean differences between groups and their SD were extracted; if not available, SD of the mean 113 
difference between groups was estimated by standard formulae from the reported standard error, 114 
CI or probability value (Higgins et al., 2019). If the median was available but not the mean, the 115 
latter was transformed from the former (Luo et al., 2018); SD was estimated from the interquartile 116 
range when only this was available (Wan et al., 2014). If trials had more than one intervention 117 
group, the data for each were combined (Higgins et al., 2019). Heterogeneity was examined using 118 
I2 statistics (Higgins & Thompson, 2002). To address heterogeneity (Higgins et al., 2019), a 119 
random-effects model was implemented for the meta-analyses if overall heterogeneity was ≥30%; 120 
otherwise, a fixed effect model was used (Higgins & Thompson, 2002). Publication bias was 121 
investigated by asymmetry testing: funnel plots were examined visually if 10 or more trials were 122 
included in the analyses (Egger et al., 1997; Sterne et al., 2011). Meta-analyses, aggregated effect 123 
sizes, CI, degree of heterogeneity, and funnel plots were computed using Review Manager 124 
(RevMan), version 5.3 (Higgins et al., 2019). 125 
 126 
Meta-analyses planned in the protocol (Chircop et al., 2019) compared (I) SMBG versus usual 127 
care and (II) structured SMBG versus unstructured SMBG, on HbA1c. Subgroup meta-analyses 128 
planned in the protocol (Chircop et al., 2019) were comparing (i) SMBG readings used to adjust 129 
therapy versus usual care, (ii) SMBG with nursing education versus usual care, (iii) SMBG with 130 
nursing education versus SMBG without nursing education and (iv) unstructured SMBG versus 131 
usual care. As per the protocol (Chircop et al., 2019), a minimum number of three trials were 132 
required for the data to be synthesized. The interpretation of the analyses was made by JC and DS 133 
independently. No disagreements (0%) arose requiring discussions, eliminating the need for a final 134 
decision being made by YK. 135 






Study Selection 138 
The electronic search resulted in the identification of 76 studies. Forty-seven studies were 139 
identified through other sources. Of 123 studies in total, five duplicates were identified. This 140 
resulted in 118 titles and abstracts being screened, with 86 being excluded. This resulted in 32 full-141 
text articles being screened for eligibility, with 11 being excluded. Reasons for exclusion include: 142 
not RCTs (n = 5), no control arm (n = 2), telemonitoring (n = 2), telecare (n = 1), and SMBG part 143 
of trial not being randomized and controlled (n = 1). In total, 18 trials reported in 21 articles are 144 
included in this review (Barnett et al., 2008; Bosi et al., 2013; Davidson et al., 2005; Durán et al., 145 
2010; Farmer et al., 2009; Franciosi et al., 2011; García de la Torre et al., 2013; Guerci et al., 2003; 146 
Kan et al., 2017; Kleefstra et al., 2010; Malanda et al., 2016; Nishimura et al., 2017; O’Kane et 147 
al., 2008; Parsons et al., 2019; Polonsky et al., 2011; Schwedes et al., 2002; Shen et al., 2019; 148 
Sodipo et al., 2017; Suriyawongpaisal et al., 2016; Williams et al., 2020; Young et al., 2017); all 149 
trials are included in the meta-analyses. The inclusion process flowchart is presented in Figure 1. 150 
<Figure1> 151 
 152 
Study Characteristics 153 
Table 1 shows the characteristics of the included trials with the number of participants, duration, 154 
and participants’ baseline HbA1c. The articles were published between 2002 and 2020. Thirteen 155 
trials investigated structured SMBG versus usual care, four trials compared structured SMBG with 156 
unstructured SMBG, and one trial  compared unstructured SMBG with usual care (Guerci et al., 157 




2003). Almost all trials had a duration of six (8 trials) or 12 (8 trials) months; one trial (Sodipo et 158 
al., 2017) had a duration of three and another (Durán et al., 2010) of 36. Thirteen trials 159 
implemented an intention-to-treat analysis, four implemented a per-protocol analysis, and one 160 
implemented both (Bosi et al., 2013). In trials investigating structured SMBG versus usual care, 161 
participants received care in diabetes, endocrinology, or specialist settings (six trials), primary 162 
settings not specific to diabetes (five trials), a range of these (Parsons et al., 2019), and a medical 163 
center (Malanda et al., 2016). In trials investigating structured SMBG versus unstructured SMBG, 164 
most participants received care in diabetes settings (Bosi et al., 2013) or primary settings 165 
(Nishimura et al., 2017; Polonsky et al., 2011) not specific to diabetes. No trials investigated 166 
SMBG with nursing education versus SMBG without nursing education, only one (Franciosi et 167 
al., 2011) investigated SMBG with nursing education versus usual care and only one (Guerci et 168 
al., 2003) investigated unstructured SMBG versus usual care; therefore, meta-analyses were not 169 
performed for these comparisons, as per the protocol (Chircop et al., 2019). Almost half (44%) of 170 
the trials investigated SMBG with readings used to adjust therapy. The therapy adjusted was 171 
pharmacotherapy, by nurses and physicians, except for two trials where investigators, whose 172 
professions were not reported, adjusted this (Barnett et al., 2008; Sodipo et al., 2017), and one trial 173 
where therapy adjusted was diet, by dietitians (Suriyawongpaisal et al., 2016). Most trials 174 
investigated participants who are not newly diagnosed (diabetes duration: > 1 year), except for 175 
four (Durán et al., 2010; Kan et al., 2017; O’Kane et al., 2008; Sodipo et al., 2017). 176 
<Table 1.> 177 
 178 
No trials reported only the median or interquartile range, eliminating the need for transformations 179 
and estimations of values by formulae respectively (Luo et al., 2018; Wan et al., 2014). Two trials 180 




included two SMBG groups: one trial (Farmer et al., 2009) with less-intensive and more-intensive 181 
monitoring and another trial (Suriyawongpaisal et al., 2016) with a seven-point and a five-point 182 
SMBG. Therefore, the intervention groups for these were combined (Higgins et al., 2019). Only 183 
data for the planned comparisons were extracted; other data, e.g. from a telemonitoring arm 184 
(Parsons et al., 2019), participants receiving insulin (Kan et al., 2017), and participants undertaking 185 
a supervised exercise program (Durán et al., 2010) were not included in meta-analyses. Overall 186 
heterogeneity (I2) was ≥30% for each analysis so random effects meta-analyses were used. One 187 
meta-analysis included ten or more trials and was investigated by asymmetry testing for 188 
publication bias (Egger et al., 1997; Sterne et al., 2011). 189 
 190 
Risk of Bias 191 
According to RoB2 (Sterne et al., 2019), eight of the 18 trials had an overall high risk of bias due 192 
to deviations from the intended interventions (Parsons et al., 2019; Polonsky et al., 2011; 193 
Suriyawongpaisal et al., 2016), missing outcome data (Barnett et al., 2008; Guerci et al., 2003; 194 
Schwedes et al., 2002), issues with randomization (Guerci et al., 2003; Kleefstra et al., 2010) and 195 
issues with reporting the result (Kan et al., 2017). No trials had a risk of bias for measuring the 196 
outcome, HbA1c. The method of measuring the outcome was appropriate: this was measured by 197 
reliable and strongly valid measurement instruments (automated blood analyzer machines) 198 
(Higgins et al., 2019; Nathan et al., 2008). Blinding was appropriate: the use of placebo and 199 
blinding of participants was not possible due to the intervention being a test carried out by 200 
themselves, therefore allocation concealment (blinding of outcome assessors) was considered 201 
(Sterne et al., 2019). (Figure 2).  202 




<Figure 2.> 203 
 204 
Analysis (I): SMBG versus usual care 205 
Fourteen trials compared SMBG to usual care. At baseline, the mean HbA1c was 8.2% (8.1, 8.3) 206 
(66 mmol/mol (65, 67), n = 1752) in the intervention and 8.2% (8.2, 8.3) (66 mmol/mol (66, 67), 207 
n = 1524) in the control groups. Almost half of the trials (43%, 6 trials) had a mean HbA1c of ≤ 8% 208 
(64 mmol/mol) at baseline in both groups. The mean difference change was negative for almost 209 
all trials (86%, 12 trials), indicating improvement in HbA1c. The weighted mean difference 210 
(WMD) was -0.3% (-0.4, -0.2) (-3 mmol/mol (-5, -2), n = 3276) with moderate heterogeneity 211 
(I2 = 57%). The forest plot is presented in Figure 3. By way of visual inspection, no outliers were 212 
noted. Asymmetry testing indicated a low probability of publication bias (Egger et al., 1997; Sterne 213 
et al., 2011). As there was moderate heterogeneity, we also examined only those trials with a high 214 
baseline HbA1c (Barnett et al., 2008; Davidson et al., 2005; Guerci et al., 2003; O’Kane et al., 215 
2008; Parsons et al., 2019; Schwedes et al., 2002; Sodipo et al., 2017; Suriyawongpaisal et al., 216 
2016). In congruence with previous reviews (Machry et al., 2018; Zhu et al., 2016), this was 217 
defined as > 8% (64 mmol/mol). In those eight trials (n = 2186), there was a significant reduction 218 
in HbA1c of -0.4% (-0.5, -0.2), -4 mmol/mol (-6, -3), and heterogeneity was reduced (I2 = 21%).   219 
<Figure 3> 220 
 221 
Analysis (II): Structured SMBG versus unstructured SMBG 222 




Four trials compared structured SMBG to unstructured SMBG. At baseline, the mean HbA1c was 223 
8.0% (7.9, 8.2) (64 mmol/mol (61, 66), n = 847) in the intervention and 7.9% (7.7, 8.1) (63 (61, 224 
65), n = 842) in the control group. Half of the trials (Bosi et al., 2013; Nishimura et al., 2017) had 225 
a mean HbA1c of ≤ 8% (64 mmol/mol) at baseline in both the intervention and control groups. The 226 
mean difference change was negative for all trials, indicating improvement in HbA1c. The WMD 227 
was that of -0.2% (-0.3, -0.1) (-2 mmol/mol (-3, -1), n = 1689) with mild heterogeneity (I2 = 30%). 228 
The forest plot is presented in Figure 4. By way of visual inspection, no outliers were noted. An 229 
accurate assessment of publication bias was not possible: asymmetry testing was not performed as 230 
there were fewer than ten trials included in this analysis (Sterne et al., 2011). 231 
<Figure 4> 232 
 233 
Subgroup analysis (III): SMBG readings used to adjust therapy versus usual care 234 
In the preplanned subgroup analysis, eight trials compared SMBG readings used to adjust therapy, 235 
versus usual care. More than half (Durán et al., 2010; Farmer et al., 2009; Franciosi et al., 2011; 236 
Young et al., 2017) had a mean HbA1c of ≤ 8% (64 mmol/mol) at baseline in both the intervention 237 
and control groups. The mean difference change was negative for all trials, indicating improvement 238 
in HbA1c. The WMD was that of -0.4% (-0.5, -0.2) (-4 mmol/mol (-6, -2), n = 1935) with moderate 239 
heterogeneity (I2 = 64%). The forest plot is presented in Figure 3. 240 
 241 
DISCUSSION 242 
This present systematic review of SMBG effects on HbA1c is the most comprehensive to date; it 243 
includes RCTs up to 30 June 2020. The review compared the effect of I) SMBG versus usual care 244 




II) structured SMBG versus unstructured SMBG and III) SMBG readings used to adjust therapy 245 
versus usual care, on glycemic control in non-insulin-treated participants with type 2 diabetes. In 246 
the primary analysis of 14 trials, SMBG resulted in significant decreases in HbA1c compared to 247 
usual care (-0.3%, -3 mmol/mol). This accords well with previous reviews of fewer participants 248 
(Mannucci et al., 2018; Zhu et al., 2016). There was moderate heterogeneity though most trials (12 249 
trials) showed decreases in HbA1c compared to usual care. Secondary analyses examining those 250 
trials with high baseline HbA1c revealed significant reductions (-0.4%, -4 mmol/mol) with good 251 
heterogeneity. Thus, the effect of SMBG may be influenced by the initial value of HbA1c, and 252 
SMBG may be more important in participants with suboptimal control. Taken together, these 253 
analyses suggest that SMBG results in moderate improvements in HbA1c, which are larger if 254 
participants have suboptimal glycemic control. 255 
 256 
The analysis comparing structured SMBG with unstructured SMBG showed a decrease in HbA1c 257 
in the structured group compared to the unstructured group (-0.2%, -2 mmol/mol) with good 258 
heterogeneity. Thirteen of the 14 trials included in the primary analysis (I) used structured SMBG. 259 
There was only one trial that compared unstructured SMBG with usual care so meta-analysis was 260 
not possible; it reported greater reductions in HbA1c in the unstructured SMBG group than usual 261 
care (Guerci et al., 2003). Thus, a structured approach appears to improve the efficacy of SMBG. 262 
 263 
In the preplanned subgroup analysis, eight trials compared structured SMBG readings used to 264 
adjust therapy, with usual care. Using readings to adjust therapy resulted in greater reductions in 265 
HbA1c (-0.4%, -4 mmol/mol) though heterogeneity was moderate suggesting differences in 266 




participant populations influence benefits observed, e.g., health literacy and behavior (Cook et al., 267 
2018; Kim et al., 2020). However, trials included in this analysis all had therapy adjusted by 268 
clinicians, and in seven of the eight trials, pharmacotherapy was adjusted; in the other trial, diet 269 
was adjusted (Suriyawongpaisal et al., 2016). If sustained long-term (Stratton et al., 2000), this 270 
improvement in HbA1c would significantly reduce diabetes-related morbidity and mortality. 271 
Secondary analyses that compared SMBG without therapy adjustment to usual care revealed no 272 
significant HbA1c improvement (-0.2% (-2 mmol/mol). Together, these analyses show structured 273 
readings better therapy adjustment. 274 
 275 
Our meta-analyses provide similar estimates of benefit to Manucci et al. (2018) in larger corpuses 276 
of trials, with seven more trials included. It is worth noting that this review did not include one of 277 
the trials (Durán et al., 2010) in the structured versus unstructured SMBG meta-analysis as, in the 278 
control group, SMBG was only initiated when it was considered appropriate and always if insulin 279 
was started (Durán et al., 2010); the use of insulin is an exclusion criterion. No previous review 280 
compared structured SMBG readings used to adjust therapy versus usual care. Our analyses show 281 
that structured SMBG readings with therapy adjustment improve HbA1c and so support expert 282 
consensus (Davies et al., 2018). Suriyawongpaisal et al. (2016) offer an explanation for this: over-283 
reliance on participant education and a lack of clarity on therapy goals. Their findings support 284 
clinicians reviewing SMBG readings and providing appropriate therapy, this is congruent with 285 
current IDF guidance and our findings (IDF, 2018; Suriyawongpaisal et al., 2016). The IDF 286 
identifies that the use of SMBG can encourage timely action, avoiding clinical inertia (a failure of 287 
initiating or intensifying therapy when indicated) (IDF, 2018; Phillips et al., 2001). The IDF 288 




recommends the prescription of SMBG only when healthcare providers can adjust therapy (i.e., 289 
have the appropriate knowledge, skills and willingness); our findings support this (IDF, 2018). 290 
 291 
These analyses show that structured SMBG with therapy adjustment leads to clinically significant 292 
improvements in HbA1c. Secondary analyses show that reductions in HbA1c are greater with higher 293 
initial HbA1c levels. Consideration should be given for SMBG as part of a wider multifactorial 294 
approach (Ji et al., 2020; Moreira et al., 2015). However, implications are for clinicians to prescribe 295 
SMBG if readings are structured with an aim for therapy adjustment based on the readings, and 296 
not prescribing unstructured SMBG. Additionally, our results suggest that participants with 297 
suboptimal glycemic control benefit most from SMBG prescription. 298 
 299 
The structured SMBG regimen to prescribe has not been established in clinical practice. The IDF 300 
offers several examples such as five-point, seven-point and ‘staggered’ (IDF, 2018). Nishimura et 301 
al. (2017) offer a less-frequent seven-point regimen: seven readings on three consecutive days 302 
once every two months without daily readings. This seven-point regimen is simple (only three 303 
days of SMBG in two months); it is easily modifiable according to participants’ and clinical needs 304 
(e.g., days which are convenient can be chosen and risk of hypoglycemia respectively), supporting 305 
individual considerations as suggested by the ADA, IDF and CDS (Davies et al., 2018; Jia et al., 306 
2019). Only one study included investigates less-frequent SMBG versus usual care; more 307 
significant decreases in HbA1c are reported (-0.6%, -6 mmol/mol) (Franciosi et al., 2011). SMBG 308 
carries significant financial burden in diabetes (participants who perform SMBG incur 80% more 309 
costs) (Grimes et al., 2016), and by reducing the number of readings with this seven-point SMBG 310 




regimen e.g., by 65% and 83% compared to daily and twice daily SMBG respectively, leads to 311 
significantly improved cost-effectiveness. Therefore, this less-frequent SMBG regimen is 312 
presented as a favorable structured SMBG regimen, both in terms of clinical- and cost-313 
effectiveness; though evaluation of this specific regimen may be merited. 314 
 315 
Strengths of this review include the systematic literature search, the use of RoB2 to assess bias, 316 
the inclusion of trials with different technical and clinical factors, and the low risk of publication 317 
bias for the trials of SMBG versus usual care. Limitations within the review include not 318 
investigating glycemic variability and health-related quality of life, funding sources (ten trials were 319 
funded by industry and three trials did not provide funding information), variability in the risk of 320 
bias with eight of the included trials having a high risk of bias, moderate heterogeneity (I2) for the 321 
SMBG versus usual care analysis, and a low number of trials (four trials) for the structured versus 322 
unstructured analysis. 323 
 324 
Conclusion 325 
This review with meta-analyses found that glycemic control is improved in non-insulin-treated 326 
participants with type 2 diabetes mellitus when clinicians adjust therapy based on structured 327 
SMBG readings. Clinicians can prescribe structured SMBG to adjust therapy based on the 328 
readings, and not prescribe unstructured SMBG. This review supports focusing on participants 329 
with suboptimal glycemic control. A SMBG regimen that significantly improves convenience and 330 
cost-effectiveness while maintaining clinical benefit is presented. Future studies can be aimed at 331 
investigating this regimen specifically. 332 
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Figure Legends 






Flowchart of the included studies. Template from: Moher et al. (Moher et al., 2015).  
Figure 2. 
Cochrane Risk of Bias 2 Traffic Light Plot: SMBG versus usual care. 
Figure 3. 
Forest plot of meta-analysis for SMBG versus usual care including SMBG readings used to 
adjust therapy versus usual care. Mean differences between intervention and control groups from 
baseline are presented for all 12 trials. The data are quantitively synthesized and presented as 
weighted mean difference. 
Figure 4. 
Forest plot of meta-analysis for Structured SMBG versus unstructured SMBG. Mean differences 
between intervention and control groups from baseline are presented for all four trials. The data 
are quantitively synthesized and presented as weighted mean difference. 
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Structured SMBG versus usual care 
Schwedes et al., 2002 6 113 – 110, 45-70 PP 6-point twice weekly SMBG interpretation I Health centers No 8.5:8.4 (69:68) -5 (-9, -1) Industry 
Davidson et al., 2005 6 43 – 45, 38-62 ITT 6-point six times weekly 
 
Diabetes program, dietary 
counselling I C 
 
Community clinic No 8.5:8.4 (70:68) -2 (-11, 6) Industry 
Barnett et al., 2008 6 271 – 248, 40-80 ITT 5-point twice weekly Hypoglycemia education   I C Specialist centers Inv 8.1:8.1 (65:65) -3 (-5, 0) Industry 
O’Kane et al., 2008 12 96 – 88, <70 ITT Eight readings weekly 
 
Structured education 
program I C 
Diabetes OP No 8.8:8.6 (73:71) -2 (-8, 3) Non-industry 
Farmer et al., 2009 12 301 – 152, ≥25 ITT 3-point twice weekly SMBG interpretation MI Rural/suburban GP centers GP 7.5:7.5 (58:58) -2 (2, 0) 
Non-
industry 
Durán et al., 2010 
(Durán et al., 2010; 
García et al., 2013) 
36 65 – 65, 18-80 ITT 6-point every three days Lifestyle session I Endocrinology OP Phy 6.6:6.7 (49:50) -6 (-7, -4) 
Non-
industry 
Kleefstra et al., 2010 12 22 – 18, 18-70 ITT 4-point twice weekly No Diabetes OP No 7.6:7.7 (60:61) 0 (-6, 6) Industry 
Franciosi et al., 2011 6 46 – 16, 45-75 ITT 2-point thrice weekly SMBG interpretation I Diabetes OP Nur,Diab 8.0:7.9 (64:63) -7 (13, 0) Industry 
Malanda et al., 2016   12 57 – 60, 45-75 PP 6-point twice weekly SMBG interpretation I Medical Center No 7.5:7.4 (59:58) 1 (-2, 4) Industry 
Suriyawongpaisal et al., 
2016 6 98 – 63, >30 PP 
 
7-point & 5-point, thrice 
weekly 
Diet counselling I Diabetes clinic Diet 8.7:8.4 (72:69) -6 (-11, -1) Not reported 
Sodipo et al., 2017 3 55 – 52, ≥18 ITT 2-point thrice weekly Structured education program I C General OP clinic Inv 8.7:8.7 (72:72) -6 (-15, 4) 
Not 
reported 
Young et al., 2017 12 141 – 147, ≥30 ITT One reading daily No Primary care practices Cli 7.6:7.5 (59:59) -1 (-4, 2) 
Non-
industry 
Parsons et al., 2019 
(Parsons et al., 2019; 
Williams et al., 2020) 
12 99 - 116, 18-80 PP 4-point twice weekly General diabetes education I C 
Diabetes, GP or 
hospital clinic Nur, GP 8.5:8.7 (70:72) -8 (-2, -5) Industry 
 
           
Unstructured SMBG versus usual care 
Guerci et al., 2003 6 345 - 344, 40-75 ITT Six readings weekly Dietary advice GP No 9.0:8.9 (75:74) -3 (-6, -1) Non-industry 
 
           
Structured SMBG versus unstructured SMBG 




Phy I 8.9:8.9 (74:74) -3 (-5, -1) Industry 
 
Bosi et al., 2013 12 501 – 523, 35-75 ITT, PP 4-pointb SMBG interpretation I Diabetes clinics Cli I 7.4:7.3 (57:56) -1 (-2, -0) Industry 
Kan et al., 2017 (Kan et 
al., 2017; Shen et al., 
2019) 
6 60 - 60, 47-70 ITT 2-pointc 30 min teachingd I C Investigation center N,Phy I C 9.6:9.5 (81:81) -6 (-13, 1) 
Non-
industry 
Nishimura et al., 2017 6 30 - 32, ≥20 ITT 7-pointe SMBG interpretation video I C 
Outpatient 
department Phy I C 7.2:7.2 (55:55) -2 (-5, 1) Industry 
Data are presented as number. 
Abbreviations: C, control group; CI, confidence interval; Diab, diabetologist; Diet, dietitian; GP, general practitioner; I, intervention group; Inv, investigators; ITT, intention-to-
treat analysis; MI, more-intensive monitoring group; Nur, nurse; OP, outpatients; Phy, physician; PP, per-protocol analysis; SMBG, self–monitoring of blood glucose. 
a. I: 7-point on three consecutive days prior to scheduled visit. C: To follow physicians’ SMBG recommendations. 
b. I: 4-point thrice weekly. C: 4-point once at baseline, six months, and 12 months. 
c. I: 2-point daily. C: usual care. 
d. Antidiabetic drugs, glycemic targets and healthy lifestyle. 
e. I: 7-point for three consecutive days once every two months. C: Thrice weekly. 
 
